title: Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
abstract: This paper reviews the clinical profile of aprepitant, the first neurokinin-1 (NK(1)) receptor antagonist to be approved for use in the prevention of chemotherapy-induced nausea and vomiting. When given to patients receiving highly emetogenic chemotherapy, aprepitant in combination with a 5-hydroxytryptamine type-3 (5HT(3)) receptor antagonist and a corticosteroid provides significantly improved protection from chemotherapy-induced nausea and vomiting over that which has been previously achievable with current antiemetics.
authors.affiliation: Kansas City Cancer Center - South, 1000 East 101st Street Terrace, Kansas City, Missouri 60131, USA. kelly.pendergrass@usoncology.com
authors.forename: Kelly
authors.initials: K
authors.lastname: Pendergrass
authors.forename: Richard
authors.initials: R
authors.lastname: Hargreaves
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Petty
authors.forename: Alexandra D
authors.initials: AD
authors.lastname: Carides
authors.forename: Judith K
authors.initials: JK
authors.lastname: Evans
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Horgan
mesh_terms: D000284:Administration, Oral; D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D000077608:Aprepitant; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced* / Q000517:prevention & control*; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1 / Q000008:administration & dosage / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D000077608:Aprepitant